On Tuesday, Following U.S. Stocks were among the “Top Gainers”:CorMedix, (NYSEMKT:CRMD), Orbital ATK, (NYSE:OA), Microvision, (NASDAQ:MVIS)

• CorMedix, (NYSEMKT:CRMD), with shares inclined 4.21%, closed at $9.15.

• Orbital ATK, (NYSE:OA), with shares jumped 4.04%, settled at $72.06.

• Microvision, (NASDAQ:MVIS), with shares climbed 3.97%, and closed at $2.62.

Latest NEWS regarding these Stocks are depicted underneath:

CorMedix, Inc. (NYSEMKT:CRMD)

CorMedix, Inc. (CRMD), a pharmaceutical corporation focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, declared that the extension to April 30, 2015 of the expiration date applies to all publicly traded warrants.

The holders of CorMedix warrants should note that the Corporation issued two tranches of warrants in 2010 with the same CUSIP number (No.21900C118). The first tranche of warrants were purchased for cash in connection with the Corporation’s initial public offering of ordinary stock in 2010, and may be exercised at the specified exercise price in exchange for registered, freely tradable shares of ordinary stock issued following a presently effective registration statement.

The second tranche of warrants was also issued in 2010 to a select group of investors in exchange for debt issued preceding to the Corporation’s initial public offering. The holders of these warrants may exercise and receive in exchange shares of unregistered ordinary stock. The Corporation intends to file a registration statement for the resale of the shares issuable upon exercise of the second tranche of warrants as soon as practicable following the filing later this week of the Corporation’s Annual Report Form 10-K.

The exercise date for both tranches of warrants, inclusive of all publicly traded warrants, has been extended from March 24, 2015 to April 30, 2015.

Holders of CorMedix warrants should contact the Corporation’s transfer agent, VStock Transfer, LLC, at the number set forth below for assistance in determining whether their respective warrants were issued in the first or second tranche. Preceding to the availability of the resale registration statement described above, upon exercise holders will not receive shares of ordinary stock free from restrictions on trading unless they can establish that their warrants were originally issued as part of the first tranche.

CorMedix Inc. is a commercial-stage pharmaceutical corporation that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix’s first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients counting neonates, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications.

Orbital ATK, Inc. (NYSE:OA)

Orbital ATK, Inc. (OA), a global leader in aerospace and defense technologies, will highlight a wide range of the corporation’s satellite and space component products at the Satellite 2015 Conference and Exhibition. The conference is being held March 16-19 at the Walter E. Washington Convention Center in Washington, D.C. The Orbital ATK display is located at Booth 8017 in the exhibit hall.

In addition to the exhibit presentation, Orbital ATK President and Chief Executive Officer David W. Thompson will take part in a panel discussion on Monday, March 16 at the conference. The panel titled, “Transformative Change Across the Value Chain” will be held from 9:00-10:00 a.m. in Room 207A at the Convention Center.

Orbital ATK, Inc. develops and produces aerospace, defense, and commercial products to the U.S. government, allied nations, and prime contractors in the United States, Puerto Rico, and internationally.

Microvision Inc. (NASDAQ:MVIS)

Microvision Inc. (MVIS), a leader in innovative ultra-miniature projection display technology, declared its 2014 operating and financial results and an overview of its 2015 business objectives.

2014 Operating Results:

2014 was a year of noteworthy accomplishments for MicroVision. Progress was made on each of its stated aims for the year, positioning the corporation for growth in 2015. The aims for 2014 were to:

• Complete development with Fortune Global 100 customer, support customer with commercialization efforts and supply key components
• Build pipeline of consumer and automotive OEM opportunities for MicroVision’s go-to-market partners that are providing display engines incorporating PicoP® display technology
• Ramp supply chain for high volume production of MicroVision components in the second half of 2014.

MicroVision, Inc. is engaged in the development of its proprietary PicoP display technology that can be used by its customers to create miniature laser display and imaging engines in the United States.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content described in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.